<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02426866</url>
  </required_header>
  <id_info>
    <org_study_id>AI266-414</org_study_id>
    <nct_id>NCT02426866</nct_id>
  </id_info>
  <brief_title>Risk of CV Events With EFV vs. EFV-free Regimens</brief_title>
  <official_title>The Risk of Cardiovascular Events Among HIV Patients Initiating Efavirenz-containing Versus Efavirenz-free Antiretroviral Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Truven health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether there is an increased risk of
      cardiovascular events (CV) with regimens containing efavirenz (EFV) versus other regimens in
      patients with HIV.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular events specifically based on incidence rate and compare the hazard between the HIV infected patient initiating efavirenz-containing antiretroviral regimen and efavirenz-free antiretroviral regimen</measure>
    <time_frame>upto 1 to 5 years</time_frame>
    <description>cardiovascular events specifically based on incidence rate and compare the hazard (myocardial infarction, stroke,percutaneous coronary intervention, coronary artery bypass graft, and composite of aforementioned events) between the HIV infected patient initiating efavirenz-containing antiretroviral regimen and efavirenz-free antiretroviral regimen</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">29612</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Patient with Efavirenz exposure</arm_group_label>
    <description>Patient with Efavirenz exposure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient without Efavirenz exposure</arm_group_label>
    <description>Patient without Efavirenz exposure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <arm_group_label>Patient with Efavirenz exposure</arm_group_label>
    <arm_group_label>Patient without Efavirenz exposure</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Commercial insurance database and Medicaid database
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Aged 18 years or older on the index date

          -  Have at least one pharmacy claim for efavirenz or a drug in the comparison cohort
             during the period spanning January 1, 2007 through December 31,2013.

          -  Clinical Modification (ICD-9) diagnosis code for HIV infection including 042 (HIV
             disease), V08 (asymptomatic HIV infection status), 795.71 (nonspecific serologic
             evidence of HIV), and 079.53 (HIV, type 2) any time prior to the index claim.

          -  Have at least 6 months (180 days) of continuous enrollment prior to the index claim

        Exclusion Criteria:

          -  Patients who have been dispensed any antiretroviral medications anytime before the
             index date including the 180-day baseline period

          -  Patients with evidence of a cardiovascular outcome of interest during the 180-day
             baseline period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2015</study_first_submitted>
  <study_first_submitted_qc>April 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2015</study_first_posted>
  <last_update_submitted>April 22, 2015</last_update_submitted>
  <last_update_submitted_qc>April 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

